How Investors May Respond To Harrow (HROW) Issuing US$50M In 8.625% Senior Notes For Growth

Simply Wall St.03-25 10:08

Harrow, Inc. recently completed a private fixed‑income offering of US$50,000,000 in 8.625% senior unsecured notes due 2030, callable and guaranteed by its wholly owned domestic restricted subsidiaries...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622045353?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-03-25 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622045353","market":"sg","top_or_hot":-1,"title":"How Investors May Respond To Harrow (HROW) Issuing US$50M In 8.625% Senior Notes For Growth","media":"Simply Wall St.","content":"<div>\n<p>Harrow, Inc. recently completed a private fixed‑income offering of US$50,000,000 in 8.625% senior unsecured notes due 2030, callable and guaranteed by its wholly owned domestic restricted subsidiaries...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/how-investors-may-respond-to-harrow-hrow-issuing-us50m-in-86\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors May Respond To Harrow (HROW) Issuing US$50M In 8.625% Senior Notes For Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors May Respond To Harrow (HROW) Issuing US$50M In 8.625% Senior Notes For Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-25 10:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/how-investors-may-respond-to-harrow-hrow-issuing-us50m-in-86><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Harrow, Inc. recently completed a private fixed‑income offering of US$50,000,000 in 8.625% senior unsecured notes due 2030, callable and guaranteed by its wholly owned domestic restricted subsidiaries...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/how-investors-may-respond-to-harrow-hrow-issuing-us50m-in-86\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/how-investors-may-respond-to-harrow-hrow-issuing-us50m-in-86","article_id":"2622045353","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/how-investors-may-respond-to-harrow-hrow-issuing-us50m-in-86","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622045353","pubTimestamp":1774404483,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Harrow, Inc. recently completed a private fixed‑income offering of US$50,000,000 in 8.625% senior unsecured notes due 2030, callable and guaranteed by its wholly owned domestic restricted subsidiaries, under Regulation S and Rule 144A.\nThe additional 2030 notes give Harrow more financial flexibility to fund growth initiatives, product development, and future business development opportunities without issuing new equity.\nWe’ll now examine how this US$50,000,000 senior unsecured notes issuance...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","BK4557":"大麻股","BK4007":"制药","ISBC":"投资者银行","HROW":"Harrow Health Inc"},"translate_title":"投资者对Harrow(HROW)发行5000万美元8.625%优先票据以促进增长有何反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1.5,"ISBC":1.5},"content_text":"Harrow, Inc. recently completed a private fixed‑income offering of US$50,000,000 in 8.625% senior unsecured notes due 2030, callable and guaranteed by its wholly owned domestic restricted subsidiaries, under Regulation S and Rule 144A. The additional 2030 notes give Harrow more financial flexibility to fund growth initiatives, product development, and future business development opportunities without issuing new equity. We’ll now examine how this US$50,000,000 senior unsecured notes issuance could influence Harrow’s investment narrative and outlook on growth execution. Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementHarrow Investment Narrative RecapTo own Harrow, you need to believe its ophthalmic portfolio can convert strong topline momentum into durable profitability while managing product concentration risk in VEVYE, IHEEZO, and TRIESENCE. The new US$50,000,000 senior unsecured notes give Harrow extra funding for launches and clinical programs in the near term, but they also modestly increase balance sheet risk. For now, this financing does not appear to change the key short term catalyst or the main execution risk in a material way. The most relevant backdrop to this note issuance is Harrow’s 2026 revenue guidance of US$350,000,000 to US$365,000,000, which already embeds ambitious growth expectations after US$272,300,000 of revenue in 2025. Using debt rather than new equity helps support that growth plan while avoiding dilution, but it also raises the bar on converting products like TRIESENCE and VEVYE into sustainable earnings to service higher fixed interest costs. Yet beneath the growth story, investors should also be aware that Harrow’s heavier reliance on debt financing means... Read the full narrative on Harrow (it's free!)Harrow’s narrative projects $586.7 million revenue and $209.0 million earnings by 2028.Uncover how Harrow's forecasts yield a $70.62 fair value, a 101% upside to its current price.Exploring Other PerspectivesHROW 1-Year Stock Price Chart Some of the more cautious analysts, who were already baking in roughly 30 percent annual revenue growth to about US$505,000,000 and almost US$99,000,000 in earnings by 2028, see Harrow’s dependence on successful new product launches as a key pressure point. You and these lower end forecasts may view the new US$50,000,000 notes as either helpful fuel or added strain, which is exactly why it can be useful to compare several viewpoints before you decide how much risk you are comfortable with.Explore 3 other fair value estimates on Harrow - why the stock might be worth just $59.00!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Harrow research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Harrow research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harrow's overall financial health at a glance.Want Some Alternatives?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.Find 58 companies with promising cash flow potential yet trading below their fair value.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Harrow might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622045353","isCrawlerRequest":true}